Quantity of comirnaty doses purchased for nz now and in the future
Erika Whittome made this Official Information request to Ministry of Health
This request has been reported as needing administrator attention (perhaps because it is vexatious, or a request for personal information)
From: Erika Whittome
Dear Ministry of Health,
How many million doses of Pfizer comirnaty (adult, child and booster) has nz already purchased and agreed to purchase in the future in any signed contracts with the manufacturer, Pfizer?
Yours faithfully,
Erika Whittome
From: OIA Requests
Kia ora Erika,
Thank you for your request for official information. The reference number
for your request is: H2022017618.
As required under the Official Information Act 1982, Manatū Hauora will
endeavour to respond to your request no later than 20 working days after
the day your request was received. If you'd like to calculate the
timeframe, you can use the Ombudsman's online calculator
here: [1]http://www.ombudsman.parliament.nz/
If you have any queries related to this request, please do not hesitate to
get in touch.
Ngā mihi
OIA Services Team
M[2]inistry of Health information releases
U[3]nite against COVID-19
show quoted sections
From: OIA Requests
Kia ora Erika
Please see attached a letter regarding your request for official
information.
Ngā mihi
OIA Services Team
Manatū Hauora | Ministry of Health
M[1]inistry of Health information releases
U[2]nite against COVID-19
show quoted sections
References
Visible links
1. https://www.health.govt.nz/about-ministr...
2. https://covid19.govt.nz/
From: Erika Whittome
Dear OIA Requests,
So 18.58 million doses purchased for a population of 5 million.
Below is From https://bailiwicknewsarchives.files.word...
Since January 2020, acts of putative national governments have violated (among other international legal instruments) the 1975 UN Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction and the 1997 UN Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on Their Destruction, under the auspices of member-state compliance with WHO International Health Regulations, 2005.
…Covid-19 'vaccines:' case study
21 USC 360bbb-3(k), [Authorization for medical products for use in emergencies, Relation to other provisions] is a crucial provision at the intersection of the six statutory pillars outlined above.
This law provides that use of EUA-covered, regulation-exempt medical countermeasure (MCM) products including masks, diagnostic tests, injectable biochemical products, and other products that would otherwise be classified and regulated as "investigational" drugs, devices and biologics, once classified as EUA covered countermeasures during a public health emergency by the HHS Secretary and his/her delegees, “shall not be considered to constitute a clinical investigation.”
Jan. 27, 2020 was the effective date of US Secretary of Health and Human Services Alex Azar's Determination that a Public Health Emergency Exists, signed Jan. 31, 2020. The determination was recorded in the Federal Register as taking effect Feb. 4, 2020. 85 Federal Register 7316. It has been extended continuously since, most recently by HHS Secretary Xavier Becerra effective March 15, 2023 and in force as of this writing in May 2023. 88 Federal Register 16644.
Effective Feb. 04, 2020, HHS Secretary Azar issued a Notice of Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID–19. 85 Federal Register 15198. The PREP Act declaration has also been extended continuously since and amended eleven times, most recently by HHS Secretary Xavier Becerra effective May 11, 2023. 88 Federal Register 30769.
Government announcements about the termination of the public health emergency notwithstanding, the PREP Act declaration remains in force as of this writing in May 2023.
To the extent that use of Covid-19 products after Feb. 04, 2020 "shall not constitute clinical investigation," use of such products is authorized even if there is no safety or efficacy data, even if such products are toxic and ineffective.
Investigators, researchers, physicians, nurses, pharmacists and other individuals involved in product dispensing, use, or administration to human beings have had and today have no legal obligations to comply with laws and regulations that apply to use of other experimental, investigational, unapproved or approved drugs, devices and biological products, including compliance with informed consent laws, medical monitoring of recipients during product use and post-administration monitoring and reporting of effects, injuries and deaths.
Recipients of such products are not legally recognized as human subjects of clinical research or patients receiving experimental, authorized or approved products, because use of the products "shall not constitute clinical investigation."
There is no stopping condition, because there is no legally-relevant clinical investigation to be stopped.
On the basis of a self-declared public health emergency and self-declared classification of products as emergency use authorized medical countermeasures, including an unreviewable determination as to the relative risks posed by a compound classified as pathogen as compared to medical countermeasure products, the Secretary of Health and Human Services can suspend informed consent obligations for those who administer regulation-exempt, EUA biochemical products and informed consent rights for those who submit to regulation-exempt EUA biochemical products, on behalf of the entire American population.
Under standard FDA regulations governing non-EUA investigational drugs, devices and biologics, "vaccinators" would be legally required to obtain such information from manufacturers and suppliers and disclose such information to biochemical product recipients prior to administration.
But classified as covered persons or qualified persons, "vaccinators" are authorized by the HHS Secretary to mischaracterize and withhold information about EUA products, including ingredients; vial contents; chain-of-custody and serialization; potential individual risks and benefits based on individual health conditions; treatment alternatives; and right to refuse treatment.
Yours sincerely,
Erika Whittome
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence